SynthesisInflammatory bowel diseases2017
Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.
Synthesis in Inflammatory bowel diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Role of fecal calprotectin in the diagnosis of neonatal necrotizing enterocolitis: a Meta analysis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Pooled it
- AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Guideline
- Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.Journal of pediatric gastroenterology and nutrition · 2018Guideline
- Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.Journal of Crohn's & colitis · 2025Trial
- Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial.Inflammatory bowel diseases · 2019Trial
- A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares.Gastroenterology · 2019Trial
- Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease course.Journal of Crohn's & colitis · 2026Article
- Feasibility and clinical utility of home-based fecal immunochemical testing for self-monitoring of disease activity in ulcerative colitis.Crohn's & colitis 360 · 2026Article
- The role of neutrophils in the pathophysiology of inflammatory bowel diseases.Periodontology 2000 · 2025Review
- Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort).Inflammatory bowel diseases · 2025Article
- Pathophysiological Links Between Inflammatory Bowel Disease and Cardiovascular Disease: The Role of Dysbiosis and Emerging Biomarkers.Biomedicines · 2025Review
- Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease.Journal of gastroenterology · 2025Article
- Irritable Bowel Syndrome in Inflammatory Bowel Disease Patients: Prevalence, Etiology, and Treatment.Gastroenterology & hepatology · 2025Article
- Applying Biomarkers in Treat-to-target Approach for IBD.Current gastroenterology reports · 2025Review
- Oral health in inflammatory bowel disease: the overlooked impact and the potential role of salivary calprotectin.BMC oral health · 2025Article
- Genetic factors that predict response and failure of biologic therapy in inflammatory bowel disease.World journal of experimental medicine · 2025Review
- Correlation of a clinical activity index in comparison to frequently measured laboratory values in inflammatory bowel disease.International journal of colorectal disease · 2025Article
- Fecal calprotectin from ileostomy output in patients with Crohn's disease.BMC gastroenterology · 2025Article
- Concentration monitoring and dose optimization for infliximab in Crohn's disease patients: a machine learning-based covariate ensemble model.Frontiers in immunology · 2025Article
- [New treatment targets for inflammatory bowel disease?]Innere Medizin (Heidelberg, Germany) · 2025Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
backgroundIn asymptomatic patients with inflammatory bowel disease (IBD), "monitoring" involves repeated testing aimed at early recognition of disease exacerbation. We aimed to determine the usefulness of repeated fecal calprotectin (FC) measurements to predict IBD relapses by a systematic literature review.
methodsAn electronic search was performed in Medline, Embase, and Cochrane from inception to April 2016. Inclusion criteria were prospective studies that followed patients with IBD in remission at baseline and had at least 2 consecutive FC measurements with a test interval of 2 weeks to 6 months. Methodological assessment was based on the second Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist.
resultsA total of 1719 articles were identified; 193 were retrieved for full text review. Six studies met eligibility for inclusion. The time interval between FC tests varied between 1 and 3 months. Asymptomatic patients with IBD who had repeated FC measurements above the study's cutoff level had a 53% to 83% probability of developing disease relapse within the next 2 to 3 months. Patients with repeated normal FC values had a 67% to 94% probability to remain in remission in the next 2 to 3 months. The ideal FC cutoff for monitoring could not be identified because of the limited number studies meeting inclusion criteria and heterogeneity between selected studies.
conclusionsTwo consecutively elevated FC values are highly associated with disease relapse, indicating a consideration to proactively optimize IBD therapy plans. More prospective data are necessary to assess whether FC monitoring improves health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.